Search research articles
Contact Us
Filters
Showing results (51-60 of 92) with videos related to
Page
of 10
Sort By:
Oncotarget
|
September 26, 2018
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
Kozo Nagai, Lihong Hou, Li Li, et al.
Haematologica
|
January 28, 2021
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, et al.
Blood
|
May 16, 2002
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
Mark Levis, Jeffrey Allebach, Kam-Fai Tse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status
Jorge E Cortes, Hagop Kantarjian, James M Foran, et al.
Blood
|
November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
Keith W Pratz, Jorge Cortes, Gail J Roboz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution
Amy E DeZern, Anthony Sung, Sharon Kim, et al.
Blood
|
September 27, 2012
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
Amy Sexauer, Alexander Perl, Xiaochuan Yang, et al.
Blood
|
September 13, 2003
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
Rui Zheng, Mark Levis, Obdulio Piloto, et al.
Cancer Research
|
March 1, 2005
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice
Obdulio Piloto, Mark Levis, David Huso, et al.
Leukemia Research
|
August 2, 2011
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase
Amir T Fathi, Omotayo Arowojolu, Ian Swinnen, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 92) with videos related to
Sort By:
Page
of 10
Oncotarget
|
September 26, 2018
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
Kozo Nagai, Lihong Hou, Li Li, et al.
Haematologica
|
January 28, 2021
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, et al.
Blood
|
May 16, 2002
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
Mark Levis, Jeffrey Allebach, Kam-Fai Tse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status
Jorge E Cortes, Hagop Kantarjian, James M Foran, et al.
Blood
|
November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response
Keith W Pratz, Jorge Cortes, Gail J Roboz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
February 18, 2011
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution
Amy E DeZern, Anthony Sung, Sharon Kim, et al.
Blood
|
September 27, 2012
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML
Amy Sexauer, Alexander Perl, Xiaochuan Yang, et al.
Blood
|
September 13, 2003
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
Rui Zheng, Mark Levis, Obdulio Piloto, et al.
Cancer Research
|
March 1, 2005
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice
Obdulio Piloto, Mark Levis, David Huso, et al.
Leukemia Research
|
August 2, 2011
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase
Amir T Fathi, Omotayo Arowojolu, Ian Swinnen, et al.
Page
of 10